Nyxoah (NYXH)

Executive Summary

Nyxoah is a Belgian medical technology company focused on developing innovative therapies for obstructive sleep apnea (OSA). Its lead product, the Genio® system, is a hypoglossal nerve stimulation device that offers a minimally invasive alternative to continuous positive airway pressure (CPAP) therapy. The Genio system has received CE mark approval in Europe and is currently under review by the U.S. Food and Drug Administration (FDA) for marketing authorization. Nyxoah's unique approach, which includes a bilateral stimulation lead and a single-incision procedure, differentiates it from competitors and addresses the unmet need for effective OSA treatments among patients intolerant to CPAP. The company reported positive topline results from its pivotal DREAM U.S. trial in early 2024, demonstrating significant reductions in apnea-hypopnea index (AHI) and oxygen desaturation index (ODI). With a strong intellectual property portfolio and a growing body of clinical evidence, Nyxoah is well-positioned to capture a significant share of the multibillion-dollar OSA market. The company's stock is publicly traded on the NYSE under the ticker NYXH.

Upcoming Catalysts (preview)

• Q1 2026FDA decision on Genio® system70% success
• Q2 2026European commercial launch of Genio® 2.085% success
• H2 2026Potential partnership or licensing deal in Asia50% success